Conference: EANM 2026
Date: October 17 - 21, 2026
Location: Vienna, Austria
Poster presentations
Authors: Joshuaine Grant, Ben Lang, Jamie Nosbisch, Amandine Manon, Diane-Charlotte Imbs, and Sarah Minucci
Authors: Hunter Stephens and Mirjam Trame, in collaboration with Telix
Meet our team
Connect with Certara’s experts at EANM to discuss how integrated modeling, simulation, and regulatory science can help advance your radiopharmaceutical development program. From candidate selection and first-in-human studies to dose optimization, clinical development, and regulatory submissions, our multidisciplinary team provides quantitative strategies that support confident decision-making at every stage.
Whether you’re developing diagnostic or therapeutic radiopharmaceuticals, we’d welcome the opportunity to discuss your specific challenges and explore practical, science-driven solutions tailored to your program.
Submit the form to request a meeting with our experts during EANM and someone from our team will reach out to schedule.
FAQs
Where can I meet Certara at EANM 2026?
Certara’s experts will be attending EANM 2026 in Vienna and are available to meet throughout the conference. Use the form on this page to request a meeting.
Will Certara be presenting at EANM 2026?
Yes. Certara has two accepted scientific posters highlighting quantitative approaches to therapeutic radiopharmaceutical development, including quantitative systems pharmacology (QSP) and population biodistribution modeling.
Who should meet with Certara at EANM?
We welcome conversations with pharmaceutical, biotechnology, and radiopharmaceutical professionals involved in clinical pharmacology, translational medicine, pharmacometrics, quantitative systems pharmacology (QSP), dosimetry, regulatory strategy, and therapeutic radiopharmaceutical development.
What can I discuss with Certara at EANM?
Our experts can discuss dose optimization, first-in-human dose selection, pharmacometrics, quantitative systems pharmacology (QSP), biologically effective dose (BED), regulatory strategy, and model-informed drug development for therapeutic radiopharmaceutical programs.
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
